Previous 10 | Next 10 |
2023-07-06 07:50:00 ET Regeneron Pharmaceuticals ' (NASDAQ: REGN) sales growth has been lackluster in recent periods. The company is hoping that a higher-dose version of its eye medication Eylea could be a catalyst for driving sales higher in the future. However, last week the Food ...
2023-07-06 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 4, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain addit...
SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP ( www.JohnsonFistel.com ) is investigating whether Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN), any of its executive officers or others violated securities laws b...
TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 3, 2023, before the U.S. financial markets open. The Company will host a conferenc...
2023-06-29 14:04:19 ET Shares of biotech heavyweight Regeneron Pharmaceuticals (NASDAQ: REGN) lost 10% of their value over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence . The double-digit decline came after...
2023-06-28 18:40:00 ET It seems Catalent (NYSE: CTLT) was apparently the reason why a key drug was refused approval by the Food and Drug Administration (FDA). According to a media report from a leading financial news agency, this is what likely happened. On this disquieting deve...
2023-06-28 10:42:32 ET Catalent ( NYSE: CTLT ) shares extended a four-day decline on Wednesday after confirming that it was the third-party manufacturer linked to the recent FDA rejection of high-dose Eylea developed by Regeneron ( REGN ). The shares of the contract manufa...
2023-06-28 08:44:32 ET Canaccord Genuity downgraded Regeneron Pharmaceuticals ( NASDAQ: REGN ) to Hold from Buy on Wednesday after the FDA declined to approve a high-dose version of its blockbuster eye disease therapy Eylea. The Complete Response Letter issued for 8 mg of af...
2023-06-27 15:09:00 ET Regeneron ( NASDAQ: REGN ) announced Tuesday that the U.S. Food and Drug Administration (FDA) declined to approve an 8 mg dose of its eye disease therapy, aflibercept. The injection at a dose of 2 mg is already marketed in the U.S. as Eylea for conditions ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...